1. Home
  2. HRMY vs HNI Comparison

HRMY vs HNI Comparison

Compare HRMY & HNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

N/A

Current Price

$27.73

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Logo HNI Corporation

HNI

HNI Corporation

N/A

Current Price

$40.49

Market Cap

2.1B

ML Signal

N/A

Company Overview

Basic Information
Metric
HRMY
HNI
Founded
2017
1944
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Office Equipment/Supplies/Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
2.1B
IPO Year
2020
1994

Fundamental Metrics

Financial Performance
Metric
HRMY
HNI
Price
$27.73
$40.49
Analyst Decision
Buy
Strong Buy
Analyst Count
10
1
Target Price
$46.70
$70.00
AVG Volume (30 Days)
1.1M
713.2K
Earning Date
05-18-2026
06-01-2026
Dividend Yield
N/A
3.33%
EPS Growth
7.97
N/A
EPS
2.71
1.11
Revenue
$868,453,000.00
$2,839,000,000.00
Revenue This Year
$19.87
$117.47
Revenue Next Year
$12.49
$3.55
P/E Ratio
$10.62
$36.75
Revenue Growth
21.51
12.37
52 Week Low
$25.52
$38.04
52 Week High
$40.87
$53.29

Technical Indicators

Market Signals
Indicator
HRMY
HNI
Relative Strength Index (RSI) 30.66 21.11
Support Level $27.66 $38.04
Resistance Level $38.91 $45.83
Average True Range (ATR) 1.25 1.48
MACD 0.08 -0.74
Stochastic Oscillator 54.02 4.59

Price Performance

Historical Comparison
HRMY
HNI

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About HNI HNI Corporation

HNI Corp is a provider of commercial furnishings and hearth products. Its two reportable segments are workplace furnishings and residential building products. The workplace furnishings segment includes furniture systems, seating, storage, tables, architectural products, ancillary products, and hospitality products. The residential building products segment includes various gas, wood, electric, and pellet-fueled fireplaces, inserts, stoves, facings, outdoor fire pits and fire tables, and accessories. The company's products are sold through independent dealers, distributors, eCommerce retailers, wholesalers, and retail outlets. A majority of the firm's revenue is generated from the Workplace furnishings segment. Geographically, it operates in the United States.

Share on Social Networks: